1.13 -0.08 (-6.72%)
VVUS
| Trade VVUS now with |
Stock Details
Last Trade:1.13 Change:-0.08 (-6.72%) Prev Close:1.21 Open: 1.19 Days Range:1.12 – 1.20 52 Week Range: 0.92 - 1.85 Volume:1375746 P/E: N/AEPS:-2.13
View AllRecent Alerts 03/11/17
Recent Alert on 03/09/17 at 9:31am
Pre-Open Movers 03/09: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (RATE) Lower (more...)
Pre-Open Movers 03/09: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (RATE) Lower (more...)
Today's Pre-Open MoversApricus Biosciences, Inc. (Nasdaq: APRI) 33.8% HIGHER; announced that it completed the sale to Ferring International Center S.A. (Ferring) of Apricus ex-U.S. assets and rights related to Vitaros®, Apricus on-demand topical... Read More
Recent Alert on 03/09/17 at 7:31am
VIVUS (VVUS) Shares Up 27% in Pre-Market Trading Following Q4 EPS / Revenue Beat
VIVUS (VVUS) Shares Up 27% in Pre-Market Trading Following Q4 EPS / Revenue Beat
Recent Alert on 03/08/17 at 6:19pm
After-Hours Movers 03/08: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (WATT) Lower (more...)
After-Hours Movers 03/08: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (WATT) Lower (more...)
Recent Alert on 01/09/17 at 9:02am
VIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH
VIVUS (VVUS) Acquires Tacrolimus and Ascomycin Rights from Selten Pharma for PAH
View AllRecent Press Releases
Press Release on 03/08/17 at 4:10pm
VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 08/06/13 at 8:00am
Arena Pharmaceuticals: Current Prescription Rates Aren't The Real Issue
Arena Pharmaceuticals: Current Prescription Rates Aren't The Real Issue